Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SHBG | P04278 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088601 | 0.97 | EPHX1 (0.94) | EPHX1TP53LMNAKDM4EGMNN | |
| SCHEMBL31262900 | 0.88 | EPHX1 (0.79) | EPHX1TP53LMNAKDM4EGMNN | |
| SCHEMBL550246 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL9011719 | 0.81 | EPHX1 (0.68) | EPHX1TP53LMNAKDM4EGMNN | |
| SCHEMBL2067551 | 0.78 | EPHX1 (0.64) | EPHX1TP53LMNAKDM4EGMNN | |
| SCHEMBL4379254 | 0.77 | EPHX1 (0.62) | EPHX1TP53LMNAKDM4EGMNN | |
| SCHEMBL9717438 | 0.77 | EPHX1 (0.62) | EPHX1TP53LMNAKDM4EGMNN | |
| SCHEMBL4241767 | 0.76 | EPHX1 (0.59) | EPHX1TP53LMNAKDM4EGMNN | |
| SCHEMBL9821330 | 0.75 | EPHX1 (0.60) | EPHX1TP53LMNAKDM4EGMNN | |
| SCHEMBL8070691 | 0.74 | EPHX1 (0.59) | EPHX1TP53LMNAKDM4EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117247338-A | N-amino-alpha-amino acid compound and synthesis method thereof | 四川大学 | 2023-12-19 | — | — | CN | claimed |
| CN-114380712-B | Synthesis method of alpha-amino amide compound | 南京工业大学 | 2023-05-09 | — | — | CN | claimed |
| CN-115286657-A | Continuous production method of hydroxymethyl phosphonate | 湖北理工学院 | 2022-11-04 | — | — | CN | claimed |
| CN-114478218-A | Preparation method of 1, 3-diketone methylated compound | 南京工业大学 | 2022-05-13 | — | — | CN | claimed |
| CN-114380712-A | Synthetic method of alpha-amino amide compound | 南京工业大学 | 2022-04-22 | — | — | CN | claimed |
| CN-108675937-B | Synthetic method of alpha-amino acid | 南京工业大学 | 2021-02-23 | — | — | CN | claimed |
| CN-110128233-B | Preparation method of deuterated alcohol compound | 南京工业大学 | 2021-02-02 | — | — | CN | claimed |
| EP-3077376-B1 | PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-16 | — | — | EP | claimed |
| US-9598397-B2 | Process for making reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-21 | — | — | US | claimed |
| US-20160297794-A1 | PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | US | claimed |
| US-7102046-B2 | By reaction of haloaromatics or arylsulfonates with olefins in presence of palladium catalyst, bulky nitrogen base and salt | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | claimed |
| WO-2005068428-A1 | METHOD FOR STABILIZING 4-HALOGENPYRIDINES WITH SECONDARY AND/OR TERTIARY AMINES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | WO | claimed |
| US-20050165239-A1 | Process for stabilizing 4-halopyridines | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | claimed |
| US-6858756-B2 | Arylation of olefins | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-22 | — | — | US | claimed |
| US-20030114707-A1 | Arylation of olefins | LANXESS DEUTSCHLAND GMBH (DE) | 2003-06-19 | — | — | US | claimed |
| US-20030105353-A1 | Process for the arylation of olefins | LANXESS DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | claimed |
| EP-0676429-B1 | Composition for urethane-based plastic lens | MITSUI CHEMICALS INC (JP) | 2000-12-27 | — | — | EP | claimed |
| EP-0827953-A2 | Method for producing N-acyl carbamate | Nippon Paint Co., Ltd. (JP) | 1998-03-11 | — | — | EP | claimed |
| US-4853481-A | FRIEDEL-CRAFTS CATALYSIS IN PRESENCE OF TERTIARY OR DIAMINES; | BASF AKTIENGESELLSCHAFT (DE) | 1989-08-01 | — | — | US | claimed |
| US-4083861-A | Unsaturated silicon organic compounds containing keto groups | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1978-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114707-A1 | Arylation of olefins | AHR, YAP1, ARNT | EPHX1 1754/4885TP53 3582/4885LMNA 4448/4885 |
| US-20050165239-A1 | Process for stabilizing 4-halopyridines | KCNH1, NISCH, KCNH2 | EPHX1 596/4885TP53 4462/4885LMNA 3209/4885 |
| US-20030105353-A1 | Process for the arylation of olefins | NEK6, JUN, AOC2 | EPHX1 2371/4885TP53 4403/4885LMNA 4789/4885 |
| US-20160297794-A1 | PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, TYMS | EPHX1 663/4885TP53 3880/4885LMNA 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.